Early transfusion of convalescent plasma improves the clinical outcome in severe SARS-CoV2 infection

Fodor, Eszter; Müller, Veronika; Iványi, Zsolt; Berki, Tímea; Kuten, Olga Pella; Ambrus, Míra; Simonyi, Ágnes; Skázel, Árpád; Madár, Ágnes; Kardos, Dorottya; Kemenesi, Gábor; Földes, Fanni; Nagy, Š.; Matusovits, Andrea; Nacsa, János; Tordai, Attila; Jakab, Ferenc; Lacza, Zsombor

doi:10.1101/2021.05.25.21257770

Cited by 2 publications

(1 citation statement)

References 36 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found an earlier administration of CPT is associated with better odds for favorable outcomes. Similarly, a number of recent studies 17 , 18 also echoed that while early application of CPT is beneficial in critically ill COVID-19 patients, late CPT is futile. However, another recent RCT reported no significant reduction of mortality rate (OR 3.04, 95% CI 0.54–17.2, p = 0.25), and the requirement for mechanical ventilation (OR 3.04, 95% CI 0.54–17.2, p = 0.25) is associated with early administration of CPT in comparison with the deferred patients.…”

Section: Resultsmentioning

confidence: 98%

Convalescent Plasma—A Light at the End of the Tunnel: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Sarkar¹,

Khanna²,

Singh³

2021

Indian Journal of Critical Care Medicine

View full text Add to dashboard Cite

In the absence of a definitive therapy during this ongoing unprecedented crisis, coronavirus disease-2019 (COVID-19) pandemic, convalescent plasma transfusion (CPT) has shown some promising results. This review summarizes the existing evidence of the efficacy of CPT in COVID-19 patients based upon scientific publications to date. We have included only the randomized controlled trials (RCTs) through an extensive screening of electronic databases up to July 31, 2021. In 19 RCTs, with a total of 16,476 COVID-19 patients we found low-quality evidence of significant reduction in mortality (odds ratio (OR) = 0.80; 95% confidence interval (CI): 0.66–0.96, I 2 = 40%), better clinical outcome when applied <7 days (OR = 2.13, 95% CI 1.28–3.53, I 2 = 0%), and improved viral clearance (OR = 2.6, 95% CI: 1.3–5.45, I 2 = 74%). Meta-regression analysis found that as a covariate, intubation on admission ( p = 0.007) had a significant impact. However, there was any significant reduction neither in duration for clinical improvement (MD = −0.79, 95% CI: −2.76–1.18, I 2 = 98%), nor in total period of hospital stay (MD = 0.02, 95% CI: −0.75–0.78, I 2 = 81%). Early application of CPT is still relevant in reducing morbidity and mortality in critically ill patients and is too early to write it off as a potential therapeutic modality for COVID-19 patients. How to cite this article Sarkar S, Khanna P, Singh AK. Convalescent —Plasma—A Light at the End of the Tunnel: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Indian J Crit Care Med 2021;25(11):1292–1300.

show abstract

Section: Resultsmentioning

confidence: 98%

Convalescent Plasma—A Light at the End of the Tunnel: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Sarkar¹,

Khanna²,

Singh³

2021

Indian Journal of Critical Care Medicine

View full text Add to dashboard Cite

show abstract

Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors

Grujic

Bujandric

Budakov-Obradović

et al. 2021

IJERPH

View full text Add to dashboard Cite

Passive immunotherapy with convalescent COVID-19 plasma (CCP) is used as a therapeutic procedure in many countries, including Serbia. In this study, we analyzed the association between demographic factors, COVID-19 severity and the reactivity of anti-SARS-CoV-2 antibodies (Abs) in Serbian CCP donors. Individuals (n = 468) recovered from confirmed SARS-CoV-2 infection, and who were willing to donate their plasma for passive immunization of COVID-19 patients were enrolled in the study. Plasma samples were tested for the presence of IgG reactive to SARS-CoV-2 spike glycoprotein (S1) and nucleocapsid antigens. Individuals were characterized according to age, gender, comorbidities, COVID-19 severity, ABO blood type and RhD factor. Total of 420 candidates (420/468; 89.74%) reached the levels of anti-SARS-CoV-2 IgG that qualified them for inclusion in CCP donation program. Further statistical analysis showed that male individuals (p = 0.034), older age groups (p < 0.001), existence of hypertension (p = 0.008), and severe COVID-19 (p = 0.000) are linked with higher levels of anti-SARS-CoV-2 Abs. These findings will guide the selection of CCP donors in Serbia. Further studies need to be conducted to assess the neutralization potency and clinical efficiency of CCP collected from Serbian donors with high anti-SARS-CoV-2 IgG reactivity.

show abstract

Early transfusion of convalescent plasma improves the clinical outcome in severe SARS-CoV2 infection

Cited by 2 publications

References 36 publications

Convalescent Plasma—A Light at the End of the Tunnel: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Convalescent Plasma—A Light at the End of the Tunnel: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors

Contact Info

Product

Resources

About